Canada · Delayed Price · Currency is CAD Hemostemix Statistics
Total Valuation
Hemostemix has a market cap or net worth of CAD 11.87 million. The enterprise value is 14.73 million.
| Market Cap | 11.87M |
| Enterprise Value | 14.73M |
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Hemostemix has 197.80 million shares outstanding. The number of shares has increased by 71.93% in one year.
| Current Share Class | 197.80M |
| Shares Outstanding | 197.80M |
| Shares Change (YoY) | +71.93% |
| Shares Change (QoQ) | +48.69% |
| Owned by Insiders (%) | 9.74% |
| Owned by Institutions (%) | n/a |
| Float | 156.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -2.39 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.12 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.49
| Current Ratio | 0.49 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.40 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -358.00% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 596.38% |
| Weighted Average Cost of Capital (WACC) | 8.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.84% in the last 52 weeks. The beta is 0.61, so Hemostemix's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -36.84% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.09 |
| Relative Strength Index (RSI) | 40.47 |
| Average Volume (20 Days) | 30,631 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.27M |
| Pretax Income | -4.71M |
| Net Income | -4.71M |
| EBITDA | -5.27M |
| EBIT | -5.27M |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 741,720 in cash and 3.60 million in debt, with a net cash position of -2.86 million or -0.01 per share.
| Cash & Cash Equivalents | 741,720 |
| Total Debt | 3.60M |
| Net Cash | -2.86M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -4.97M |
| Book Value Per Share | -0.02 |
| Working Capital | -883,083 |
Cash Flow
| Operating Cash Flow | -4.53M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 46 |
| Net Borrowing | -500,215 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Hemostemix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -71.93% |
| Shareholder Yield | -71.93% |
| Earnings Yield | -39.72% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 30, 2020. It was a reverse split with a ratio of 0.05.
| Last Split Date | Dec 30, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |